In a phase I clinical trial led by UT Southwestern Medical Center, a short interfering RNA drug directed to tumor cells effectively disrupted HIF2α, a key driver of clear cell renal cell carcinoma.
Mail-in self-collection tests for human papillomavirus more than doubled cervical cancer screening participation among never- and under-screened U.S. women, according to a first-of-its-kind study from researchers at the University of Texas MD Anderson Cancer Center.
